钆特酸葡胺(Gadoterate Meglumine) - 在研适应症：血管疾病，造影剂_专利_临床

概要

基本信息

药物类型

造影剂、小分子化药

别名

DOTA-gadolinium meglumine、DOTA-Gd meglumine、Gadolinium-DOTA meglumine

+ [17]

靶点-

作用方式

增强剂

作用机制

磁共振成像增强剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Guerbet SAGuerbet Japan KK

非在研机构-

权益机构

威智医药股份有限公司

Zydus Lifesciences Ltd.

最高研发阶段批准上市

首次获批日期

日本 (2000-09-22),

造影剂

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C23H42GdN5O13

InChIKeyRYHQMKVRYNEBNJ-BMWGJIJESA-K

CAS号92943-93-6

关联

54

项与钆特酸葡胺相关的临床试验

NCT06600880

/ Not yet recruiting临床1期IIT

Neuronavigation-guided Focused Ultrasound-induced Blood-brain Barrier Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a single-element transducer with neuronavigation guidance. Preliminary results from our phase 1a study demonstrate that our neuronavigation-guided FUS system was capable of safely and transiently open the BBB in participants with AD. The information collected in this new study may be used to design future clinical trials to ultimately provide a viable alternative for treatment of AD in a safe and noninvasive manner.
Our secondary objective includes the assessment of the therapeutic efficacy of FUS-BBBO in reducing amyloid beta and neurofibrillary tangles, the main hallmark pathologies of AD, using PET tracers. Based on our preclinical studies in AD transgenic mouse models, FUS-BBBO alone was able to reduce both the amyloid beta and tau protein load, resulting in improvements in behavioral tasks assessing memory. Therefore, in this new study, the effect of FUS-BBBO on the amyloid beta and tau protein load in patients with AD will be assessed through the use of PET tracers.

开始日期2026-08-01

申办/合作机构

Columbia University

NCT07348640

/ Not yet recruiting临床3期

A Prospective, Multi-National, Randomized, Double-Blind, Crossover Study to Evaluate the Efficacy and Safety of Gadopiclenol-enhanced MRA Compared to Gadoterate Meglumine-enhanced MRA in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

Compare the diagnostic performance of gadopiclenol against gadoterate meglumine in patients with vascular diseases of supra-aortic, peripheral, or abdominal / renal arteries using MRI

开始日期2026-02-02

申办/合作机构

Guerbet SA

[+1]

CTIS2024-518549-27-00

/ Recruiting临床4期

Efficacy of Reduced Gadolinium Dose in Contrast-Enhanced Breast MRI

开始日期2025-08-14

申办/合作机构

Radboud Universitair Medisch Centrum

100 项与钆特酸葡胺相关的临床结果

登录后查看更多信息

100 项与钆特酸葡胺相关的转化医学

登录后查看更多信息

100 项与钆特酸葡胺相关的专利（医药）

登录后查看更多信息

699

项与钆特酸葡胺相关的文献（医药）

2026-03-01·AMERICAN JOURNAL OF NEURORADIOLOGY

Leptomeningeal Vascularity in Gadopiclenol-Enhanced Pediatric Brain MRI

Article

作者: Gee, Michael S ; Ferraciolli, Suely Fazio ; Husseini, Jad S ; Machado-Rivas, Fedel ; Griffin, Harry ; Cortes-Albornoz, Maria Camila ; Valencia, Sergio ; Jaimes, Camilo ; Cartmell, Samuel

BACKGROUND AND PURPOSE:

Gadolinium-based contrast agents (GBCAs) are essential in pediatric neuroimaging, enabling visualization of pathology that disrupts the blood-brain barrier. Gadopiclenol is a new macrocyclic GBCA with higher T1 relaxivity, permitting a 50% dose reduction while maintaining diagnostic quality. However, it is unknown whether this higher relaxivity alters background extra-axial vascular enhancement. We hypothesized that gadopiclenol, despite its lower dose, would increase background enhancement on postcontrast pediatric brain MRI compared with gadoterate meglumine (Gd-DOTA).

MATERIALS AND METHODS:

In this retrospective observational study, 302 contrast-enhanced brain MRI studies in patients aged 2-18 years were reviewed: 151 with gadopiclenol (0.05 mmol/kg) and 151 with Gd-DOTA (0.1 mmol/kg). Postcontrast sequences included 3D T1 spin-echo (SE), 3D T1 spoiled gradient-echo (SPGR), 2D T1 TSE, and 2D FLAIR. Two neuroradiologists established binary enhancement categories based on sulcal enhancement thresholds (high versus low). One reader assigned scores for all studies; a second reader evaluated a subset for interobserver agreement. Logistic regression assessed the association between contrast agent and high enhancement, adjusting for age, sex, anesthesia, and scanner field strength.

RESULTS:

Gadopiclenol was independently associated with significantly greater odds of high extra-axial enhancement on all T1-weighted sequences: 3D T1 SE (OR = 10.2; P < .001), 3D T1 SPGR (OR = 10.7; P < .001), and 2D T1 TSE (OR = 14.0; P < .001). Anesthesia was also an independent predictor of high enhancement on 3D SE and SPGR. On 2D FLAIR, contrast agent had no effect; instead, younger age was associated with high enhancement (P = .022), with an age-anesthesia interaction suggesting attenuation of this effect under sedation. Interobserver agreement was moderate to substantial (κ = 0.530-0.632).

CONCLUSIONS:

Gadopiclenol increases background extra-axial enhancement on T1-weighted postcontrast sequences in pediatric brain MRI, likely reflecting its higher relaxivity. Radiologists should be aware of this effect to avoid misinterpretation as leptomeningeal pathology. Postcontrast FLAIR remains unaffected and continues to serve as a reliable sequence for detecting true meningeal disease.

2026-02-01·Oral Surgery Oral Medicine Oral Pathology Oral Radiology

Dynamic contrast-enhanced magnetic resonance imaging for distinguishing vital and non-vital teeth in jaw lesions: a pilot study

Article

作者: Taguchi, Miharu ; Nomura, Yoshikazu ; Nakamura, Shin ; Miura, Masahiko ; Imaizumi, Akiko ; Kume, Sakiko ; Kuribayashi, Ami ; Watanabe, Hiroshi ; Tomisato, Hiroshi ; Yomtako, Supasith ; Oki, Arisa

OBJECTIVE:

We evaluated the effectiveness of dynamic contrast-enhanced magnetic resonance imaging (MRI) in distinguishing vital and non-vital teeth using a time-intensity curve pattern.

STUDY DESIGN:

We retrospectively analyzed patients who underwent dynamic contrast-enhanced MRI examinations, including those with jaw lesions and vital test results. The vital status of the dental pulp was assessed using the electric pulp test. MRI was performed using a 3T scanner and a 16-channel head and neck coil, with intravenous administration of gadoterate meglumine. Two radiologists measured signal intensity using T1-weighted imaging, T2-weighted imaging, and gadolinium-enhanced T1-weighted imaging, while time-intensity curve classification was evaluated using time-resolved angiography with interleaved stochastic trajectory images.

RESULTS:

We analyzed 26 vital and 15 non-vital teeth, using the signal- and time-intensity curve classifications. Signal intensity measurements showed no significant differences between vital and non-vital teeth on T1-weighted imaging, gadolinium-enhanced T1-weighted imaging, and T2-weighted imaging. Time-intensity curve classification effectively distinguished between increasing- and non-increasing-type teeth. Only one case showed a discrepancy between the time-intensity curve and electric pulp test, but accuracy remained high at 98%.

CONCLUSION:

Time-intensity curves derived from dynamic contrast-enhanced MRI accurately differentiated vital from non-vital teeth in jawbone lesions, comparable to the electric pulp test.

2026-02-01·JOURNAL OF NUCLEAR CARDIOLOGY

Evaluation of Gd-DOTA as a marker for myocardial blood flow using 68Ga-DOTA and 15O-water PET

Article

作者: Kvernby, Sofia ; Rischpler, Christoph ; Kero, Tanja ; Velikyan, Irina ; Sörensen, Jens ; Lubberink, Mark ; Eggers, Kai M

BACKGROUND:

Gadolinium-DOTA and similar MRI contrast agents are suggested as markers for myocardial blood flow (MBF). Contrary to MRI, the PET signal is directly proportional to radioactivity concentration and hence a PET analogue of Gd-DOTA could be used to assess the kinetics of DOTA-based agents without the challenges of measuring Gd concentrations with MRI. The aim of the present work was to assess the suitability of Gd-DOTA as a marker of MBF by comparing ⁶⁸Ga-DOTA as a PET analogue of Gd-DOTA to the gold standard for non-invasive measurement of MBF, ¹⁵O-water PET.

METHODS AND RESULTS:

24 patients underwent dynamic ¹⁵O-water-PET during rest and pharmacological stress followed by ⁶⁸Ga-DOTA-PET and Gd-DOTA dynamic contrast enhanced MRI on an integrated PET/MR scanner. ⁶⁸Ga-DOTA-PET was analysed using single-tissue and two-tissue irrreversible compartment models. The DCE MRI perfusion data was analysed using a single-tissue reversible compartment model. K₁ of ⁶⁸Ga-DOTA was compared with ¹⁵O-water. Permeability-surface area product for ⁶⁸Ga-DOTA was estimated using the Renkin-Crone equation. Kinetics of ⁶⁸Ga-DOTA were well-described by a single-tissue compartment model. The permeability surface area product of ⁶⁸Ga-DOTA was 0.70+0.15×MBF (mL/cm³/min), corresponding to an extraction of around 30% at typical hyperemic MBF values. Average whole myocardium ⁶⁸Ga-DOTA K₁ values ranged between 0.35 and 1.36 mL/cm³/min compared to 0.68 and 4.55 mL/cm³/min for ¹⁵O-water. ⁶⁸Ga-DOTA and Gd-DOTA K₁ values showed no significant differences. The correlation between ⁶⁸Ga-DOTA MBF and ¹⁵O-water MBF was moderate (r²=0.66).

CONCLUSIONS:

Extraction of DOTA is low and depends on flow resulting in a high variability and uncertainty of hyperemic MBF values.

139

项与钆特酸葡胺相关的新闻（医药）

2026-03-31

·普利制药

【招商】安徽普利硝普钠原料药获中国上市许可，加速布局全球心血管急救药物市场

安徽普利硝普钠原料药获中国上市许可 INVESTMENT PROMOTION 诚邀合作，共赢未来 ▸2026 近日，安徽普利药业有限公司（以下简称“安徽普利”）正式获得国家药品监督管理局（NMPA）签发的硝普钠化学原料药上市申请批准通知书（登记号：Y20240001218）。这是安徽普利在心血管急救类药物原料药布局中的又一关键突破，标志着公司高品质硝普钠原料药正式获准进入国内市场。 1 全球市场价值显著，核心需求高度集中硝普钠是一种强效、速效的血管扩张剂，被广泛应用于重症监护、急诊及心血管内科等临床场景，是高血压急症治疗的经典药物。多项临床研究和医学指南将其列为高血压急症的首选或核心治疗药物。作为临床必需的一线急救药物，硝普钠在全球范围内拥有明确且稳定的市场需求。 2020年至2024年五年间，全球硝普钠原料药累计消耗量近2000公斤，累计制剂销售额超过1.76亿美元。这一体量充分体现了硝普钠作为急救一线药物的临床价值与市场刚性。从全球需求分布来看，硝普钠的消耗集中于少数核心国家。以2024年数据为例，中国、巴西、美国是全球前三大市场，三国原料消耗量合计占全球总量的96%以上。其中，中国以277.69公斤的年消耗量位居全球首位，占比高达78.1%，是该品种全球供应链中当之无愧的核心目标市场。 2 全球注册布局稳步推进，覆盖欧亚拉美三大区域安徽普利秉持国际化战略，同步推进硝普钠原料药在全球主流市场的注册工作，目前已取得显著进展：安徽普利硝普钠原料药已成功获批进入中国、欧洲市场，同时巴西也在审评中。结合全球市场结构，中国、巴西、欧洲三大规范市场合计占全球硝普钠原料药消耗量的96%以上。安徽普利凭借在中欧巴西三大核心市场的注册布局，已实现对全球主流原料药需求区域的全面覆盖。 3 普利制药集团制剂布局形成协同优势硝普钠原料药的获批，是普利制药深化“原料制剂垂直一体化”战略的重要实践。在制剂端，普利制药集团已构建起覆盖全球的硝普钠制剂产品矩阵。截止目前，普利制药硝普钠注射液已在中国、美国、加拿大、澳大利亚、德国、奥地利、沙特阿拉伯、泰国、英国共9个国家或地区获批，在中国香港评审中。硝普钠氯化钠注射液已在美国获批。随着本次安徽普利硝普钠原料药在中国获批上市，以及集团硝普钠注射液、硝普钠氯化钠注射液等制剂产品的全球布局，普利制药在该品种上实现了从核心原料到高端制剂的垂直整合，进一步强化了供应链的自主可控能力，为服务全球客户构建了更为稳固的供应链基础。 4 产品核心优势 1 产品质量优势 1）产品质量稳定可靠，关键指标优于药典标准； 2）可根据客户需求提供定制化粒度分布，满足不同制剂工艺要求。 2 规模与供应优势 1）拥有专用产线，保障工艺稳定与持续供货； 2）年产能充足，可同时满足国内与国际市场的批量需求。 3 注册法规优势本品已在中、欧、巴三大市场进行原料药注册：欧洲CEP：2024-357-Rev 00（已获批）中国登记号：Y20240001218（状态：A）巴西DIFA：25351462833202497（审评中） 5 关于安徽普利安徽普利药业有限公司，成立于2018年，坐落于安庆国家高新技术产业开发区。是一家活性原料专业供应商，向全球医药、保健和护肤领域提供化学合成、生物合成的高品质特色原料。安徽普利药业拥有强大高效的研发和生产团队、配备现代化生产设施、建立严格地欧美高端原料药cGMP质量体系和高标准EHS体系，为客户提供高品质原料药和中间体的同时，也提供CDMO、工艺技改等。公司目前拥有3个符合欧美中GMP标准的API 生产车间、10条生产线，357台多功能设备。依托强大的研发能力和技术转化能力，已完成造影剂（钆特酸葡胺、钆特醇、钆布醇、碘美普尔、碘普罗胺、碘佛醇、碘帕醇、碘克沙醇等）、合成生物学（司美格鲁肽、依克多因、红景天苷）、抗肿瘤（环磷酰胺）、其他原料药（氢氧化镁、阿普斯特、克立硼罗、伏立康唑、盐酸美金刚）、其他药用辅料（DOTA、SNAC、磺丁基-β-环糊精钠、卡特利多钙、考布曲钙）等系列产品的商业化研发与生产。欢迎垂询，欢迎合作！业务联系：lisubin@hnpoly.com <<< END >>>

2026-03-03

·北陆药业

【新品】北陆药业碘普罗胺注射液获批

近日，北陆药业收到国家药品监督管理局核准签发的碘普罗胺注射液的《药品注册证书》。碘普罗胺注射液原研企业系德国拜耳（Bayer），适应症为：用于诊断用药。碘普罗胺注射液已纳入国家医保甲类药目录。根据米内网数据显示，在中国三大终端六大市场，碘普罗胺注射液2024年销售额超过16亿元，2025年一季度以2.78%的增速增长至超4亿元。碘普罗胺注射液按照化学药品4类获批，视同通过仿制药质量和疗效一致性评价，进一步丰富了公司碘类对比剂产品的布局，对比剂产品线更加多元化。公司控股子公司浙江海昌药业股份有限公司碘普罗胺原料药于2025年获批上市，碘普罗胺注射液“原料药+制剂”的经营模式已成型。截至目前，公司已拥有丰富的碘类和钆类对比剂产品集群。其中，碘类对比剂主要包括碘海醇注射液、碘帕醇注射液、碘克沙醇注射液、碘美普尔注射液及本次获批的碘普罗胺注射液；钆类对比剂方面，公司已布局钆喷酸葡胺注射液、钆贝葡胺注射液、钆布醇注射液及钆特酸葡胺注射液四款MRI对比剂，涵盖大环状钆类对比剂及线型钆类对比剂。丰富的产品有利于更好地满足临床不同用药需求，能够为各级医疗机构提供更全面、更高质量的诊断解决方案，进而提升公司产品的市场竞争力。公司将积极开展新产品上市的各项准备工作，并尽快将产品推向市场。往期推荐 01 北陆药业25年业绩预喜：净利润同比增幅显著！ 02 北陆药业关于九味镇心颗粒添加矫味剂的说明 03 【喜报】北陆药业全资子公司香港遠至取得安神助眠冲剂【玖卫】香港中成药注册证明书识别二维码关注我们

2026-03-03

·普利制药

【招商】“双重检验”获官方认可——安徽普利药业收到钆布醇原料药《药品GMP符合性检查告知书》

安徽普利药业收到钆布醇原料药《药品GMP符合性检查告知书》 INVESTMENT PROMOTION 诚邀合作，共赢未来 ▸2026 近日，海南普利制药股份有限公司（以下简称“公司”）全资子公司安徽普利药业有限公司（以下简称“安徽普利”）收到安徽省药品监督管理局颁发的《药品GMP符合性检查告知书》，所涉产品为：原料药（钆布醇）。本次钆布醇现场检查于2025年12月进行，采用依申请与依职责合并模式——在钆布醇GMP符合性检查基础上，专家组同步对氢氧化镁、环磷酰胺、钆特酸葡胺三个品种开展了常规GMP符合性检查，合并检查的结论均为“符合要求”。本次《药品GMP符合性检查告知书》的获得，表明安徽普利钆布醇原料药产品及生产线满足GMP要求，这不仅是对12月那次高强度检查的官方认可，更是对公司质量管理体系的权威背书。 1 普利制药钆布醇原料药优势钆布醇是一种兼具高浓度和高弛豫率的大环状非离子型钆对比剂，显影更清晰，并且集合了对比增强成像的有效性和安全性，适用于全身全年龄段（包括足月新生儿）检查，包括肾功能不全患者。市场数据：全球钆布醇需求持续增长根据最新市场数据显示，截至2025年9月的12个月内，全球钆布醇原料API消耗量已达 81.65吨，同比增长 8.1%，市场需求持续扩大。从区域消耗分布看，美国、欧洲等市场是钆布醇的核心消耗区域。其中：美国：25.5吨（占比 31.2%）、其他欧洲地区（含土耳其等）：24.9吨（占比 30.5%）、欧盟五国：9.6吨（占比 11.7%）；至此，安徽普利钆布醇原料药已获得中国、美国、欧盟、土耳其等核心市场的准入资格，覆盖全球绝大多数主流市场。普利制药不仅实现了原料药的全球布局，其制剂产品同样在国际市场取得重大突破。钆布醇注射液属于普利制药的原料制剂一体化品种，其原料来自海南普利制药股份有限公司子公司安徽普利药业有限公司。普利制药的钆布醇注射液已于2023年3月成功获得美国食品药品监督管理局（FDA）的上市许可（ANDA号：217480）。安徽普利钆布醇原料药在中美欧等市场的原料药备案/登记情况： ①US DMF号为039149（状态：A ；已收到正式批准信）; ②CN登记号为Y20240000083，(状态: A ；已批准在上市制剂使用）； ③CEP证书号：CEP 2024-082- Rev 00； ④获得出口欧盟原料药证明文件（WC证书），获得土耳其市场的入场资格。 2 关于安徽普利安徽普利药业有限公司，成立于2018年，坐落于安庆国家高新技术产业开发区。是一家活性原料专业供应商，向全球医药、保健和护肤领域提供化学合成、生物合成的高品质特色原料。安徽普利药业拥有强大高效的研发和生产团队、配备现代化生产设施、建立严格地欧美高端原料药cGMP质量体系和高标准EHS体系，为客户提供高品质原料药和中间体的同时，也提供CDMO、工艺技改等。公司目前拥有3个符合欧美中GMP标准的API 生产车间、10条生产线，357台多功能设备。依托强大的研发能力和技术转化能力，已完成造影剂（钆特酸葡胺、钆特醇、钆布醇、碘美普尔、碘普罗胺、碘佛醇、碘帕醇、碘克沙醇等）、合成生物学（司美格鲁肽、依克多因、红景天苷）、抗肿瘤（环磷酰胺）、其他原料药（氢氧化镁、阿普斯特、克立硼罗、伏立康唑、盐酸美金刚）、其他药用辅料（DOTA、SNAC、磺丁基-β-环糊精钠、卡特利多钙、考布曲钙）等系列产品的商业化研发与生产。欢迎垂询，欢迎合作！业务联系：lisubin@hnpoly.com <<< END >>>

上市批准申请上市引进/卖出

100 项与钆特酸葡胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03355	钆特酸葡胺	V08CA02	DB09132

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
血管疾病	美国	Guerbet LLC	2013-03-20
造影剂	日本	Guerbet Japan KK	2000-09-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
中枢神经系统疾病	临床3期	阿根廷	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	奥地利	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	巴西	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	智利	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	法国	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	德国	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	意大利	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	韩国	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	西班牙	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	英国	Guerbet LLC	2010-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01806740 (DCE-MRI, CTgov)	临床4期	肝细胞癌	37	Gadoterate meglumine	膚顧餘簾遞窪鑰選遞鏇(襯製鏇餘鬱顧餘艱繭獵) = 選醖憲淵範築製憲製鹹糧範繭選鬱餘壓鹽餘醖 (膚鑰製鹽鏇窪繭簾齋繭, 繭鹹選網齋遞齋衊淵淵 ~ 餘鏇壓糧願窪壓顧襯範) 更多	-	2019-08-08
NCT02411201 (CTgov)	临床4期	-	51	DOTAREM	觸獵衊願糧憲窪鬱構醖(網窪壓糧鑰齋範糧鹹壓) = 願憲襯製願艱膚襯醖鑰遞鬱餘鹽鹹憲窪鹽艱襯 (積獵壓糧鑰餘網鏇膚膚, 顧蓋蓋餘艱遞鹹壓餘鏇 ~ 願網蓋醖顧鬱積醖蓋壓) 更多	-	2017-03-09
NCT02070380 (BENEFIT, CTgov)	临床4期	脑疾病 \| 脑癌	179	Dotarem (MultiHance 0.1 mmol/kg Arm (Reader 1))	願窪衊壓廠範簾餘蓋夢 = 獵製鏇窪衊醖觸夢鹹鏇顧顧糧構鬱願夢願艱獵 (膚鹽膚鏇壓範糧構觸齋, 鹽膚鹹積淵願醖壓衊繭 ~ 選鹽積鑰網鏇簾廠觸範) 更多	-	2017-01-10
				Dotarem (MultiHance 0.1 mmol/kg Arm (Reader 2))	願窪衊壓廠範簾餘蓋夢 = 壓醖築艱壓遞簾糧鏇夢顧顧糧構鬱願夢願艱獵 (膚鹽膚鏇壓範糧構觸齋, 鹹鹽鬱網鏇齋襯鏇顧獵 ~ 構網遞衊鬱壓網餘醖鹽) 更多
NCT02034708 (REMIND, CTgov)	临床4期	脑癌	279	Gadovist (Gadovist® (Reader 1))	淵簾範鹽憲簾蓋襯壓淵 = 範醖構廠築淵鹹糧觸廠醖築繭餘蓋艱餘窪醖壓 (築廠製齋簾衊廠獵憲膚, 範壓顧餘襯艱築鏇鹹網 ~ 壓選鹹憲簾餘簾鬱廠糧)	-	2016-10-25
				Dotarem (Dotarem® (Reader 1))	淵簾範鹽憲簾蓋襯壓淵 = 積選糧衊築願餘壓夢蓋醖築繭餘蓋艱餘窪醖壓 (築廠製齋簾衊廠獵憲膚, 蓋願簾獵蓋範範鬱廠積 ~ 鬱糧鹽遞遞憲餘鹹觸鬱)
NCT00650845 (RESCUE, CTgov)	临床4期	肾功能不全 \| 造影剂	135	Dotarem® (Dotarem®-Enhanced MRI)	膚餘選廠鬱築齋廠齋網 = 選壓壓壓壓膚衊觸蓋簾膚製憲遞淵選構夢夢範 (糧淵鏇製廠淵簾襯艱膚, 願獵鬱顧網遞膚網製製 ~ 鹽遞窪夢膚醖廠衊積範) 更多	-	2015-06-09
				non-enhanced MRI (Non-enhanced MRI)	膚餘選廠鬱築齋廠齋網 = 廠夢範餘蓋製艱鏇夢網膚製憲遞淵選構夢夢範 (糧淵鏇製廠淵簾襯艱膚, 製齋襯簾遞襯築鬱簾觸 ~ 顧鹽鑰積積願繭壓廠選) 更多
NCT01449266 (CTgov)	临床1期	终末期肾脏病	10	Dotarem	選構遞築鏇鏇構糧餘夢(鏇願鏇壓壓糧築鑰網齋) = 鹽壓築鏇鹽鹹願廠鹽鹽積網鏇簾積積繭製糧餘 (艱鑰襯淵鹽範膚選鑰鹹, 遞衊壓築醖淵糧夢繭遞 ~ 膚鹽膚築觸醖網觸鏇醖) 更多	-	2015-06-08
NCT01211873 (SENTIO, CTgov)	临床3期	中枢神经系统疾病 \| 中枢神经系统肿瘤	416	gadoterate meglumine (Dotarem (Gadoterate Meglumine ))	範觸憲築膚夢糧獵餘齋(鹹衊築糧製繭網壓餘選) = 觸觸鏇遞鏇築願艱壓構壓願齋淵遞膚顧鹽願鹽 (醖鑰築壓蓋簾憲鏇醖衊, 齋憲簾鹹鏇構鏇鏇淵壓 ~ 夢簾廠構築夢蓋網繭鏇) 更多	-	2014-05-29
				Magnevist (Magnevist (Gadopentetate Dimeglumine))	範觸憲築膚夢糧獵餘齋(鹹衊築糧製繭網壓餘選) = 夢憲艱鹹鏇製觸簾襯蓋壓願齋淵遞膚顧鹽願鹽 (醖鑰築壓蓋簾憲鏇醖衊, 觸廠鹹衊蓋鬱製範衊淵 ~ 鹹積製選夢積積餘夢壓) 更多
ASN2013	临床1期	血液透析并发症	10	Gadoterate Meglumine	網憲糧齋鏇糧顧繭鹽簾(繭憲願壓獵積鑰鏇淵鏇) = No Aes related to gadoterate were reported. No Aes occurred at the injection site during the observation period. There were no clinically relevant changes in mean laboratory values and vital signs. No cases of Nephrogenic Systemic Fibrosis have been reported so far. 繭積遞蓋鏇衊衊簾範醖 (艱壓夢積構夢鏇齋齋窪 )	积极	2013-11-05
NCT01026389 (DALIA, CTgov)	临床4期	外周动脉闭塞性疾病 \| 外周动脉疾病 \| 血管动脉疾病	189	Gadovist (Gadovist)	獵壓遞獵夢獵觸鹹獵醖(鹹網顧夢醖鬱齋餘衊鏇) = 願簾簾齋鏇構衊構繭鬱簾餘壓艱鏇襯選憲選獵 (醖繭膚遞憲網窪淵醖繭, 19.6) 更多	-	2012-12-11
				Dotarem (Dotarem, Interventional)	獵壓遞獵夢獵觸鹹獵醖(鹹網顧夢醖鬱齋餘衊鏇) = 鬱蓋壓壓餘齋齋鏇憲構簾餘壓艱鏇襯選憲選獵 (醖繭膚遞憲網窪淵醖繭, 16.1) 更多